retatrutide 1 month results Phase III study demonstrates 30% weight loss Retatrutide vs Survodutide: 24% vs

Initially developed for type 2 diabetes management, GLP-1 agonists effectively promote weight loss in preclinical and clinical studies [11] [12], leading to their investigation and subsequent approval for obesity treatment in non-diabetic patients

Some experience side effects like cramping, nausea, and diarrhea

Biliary and gallbladder symptoms: As a class effect observed with GLP-1 receptor agonists, there is a potential signal for gallbladder-related problems

Studies of both mice and humans show the anti-inflammatory effects (such as reductions in TNF-) occur within hours, suggesting some actions are independent of weight loss or long-term metabolic change

10.1155/2018/3705389 Mediators Inflamm